Servier's $1.55 billion Becker muscular dystrophy drug fails Phase 3 trial
French drugmaker Servier said Tuesday that sevasemten failed to slow Becker muscular dystrophy in the long, placebo-controlled Phase 3 GRAND CANYON trial. The company bought the experimental medicine in June for $1.55 billion in cash, plus about $1 billion in potential milestones. Originally developed by Edgewise Therapeutics, the drug had shown promise in a smaller randomized study, making the Phase 3 outcome a surprise for both Servier and patients. Becker muscular dystrophy currently has no approved treatments. Servier said GRAND CANYON’s results “are not aligned with certain findings observed in prior clinical studies” and is conducting a comprehensive analysis of the full dataset together with earlier clinical data to better understand the findings.
Continue in the app — vote & join in ➔